

# Reference Data

## Forecast for the year ending March 31, 2021: Financial Highlights (Half year/Full year)



	FY2018/3	FY2019/3	FY2020/3			FY2021/3 Forecast		
Billions of yen	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Revenue	717.0	708.6	291.0	300.0	591.0	175.6	274.4	450.0
<b>Operating Profit</b>	56.2	82.6	17.5	-10.8	6.7	-46.6	-18.4	-65.0
% vs Revenue	7.8%	11.7%	6.0%	-3.6%	1.1%	-26.5%	-6.7%	-14.4%
Profit before income taxes	56.2	87.9	20.1	-8.3	11.8	-38.8	-21.2	-60.0
% vs Revenue	7.8%	12.4%	6.9%	-2.8%	2.0%	-22.1%	-7.7%	-13.3%
Profit attributable to owners of the parent	34.7	66.5	16.3	-8.7	7.6	-31.5	-10.5	-42.0
% vs Revenue	4.8%	9.4%	5.6%	-2.9%	1.3%	-17.9%	-3.8%	-9.3%
EPS	¥87.76	¥167.86	¥19.93			-¥114.40		
Annual Dividends	¥36	¥60	¥40			¥20		
ROE	6.3%	11.2%	1.3%			-8.5%		
FCF	90.2	43.5		-4.8		-12.1	undecided	undecided
Exchange Rate:								
US \$	¥111	¥111	¥109	¥109	¥109	¥107	¥105	¥106
EURO	¥130	¥128	¥121	¥120	¥121	¥121	¥120	¥121

Note: Beginning in FY2019/3, some sales promotion costs will be deducted from revenue. Said costs had formally been posted in SG&A. Approximately ¥8.3B has been deducted from FY2019/3 revenue.

## Forecast for the year ending March 31, 2021: Financial Highlights by Segments (Half year/Full year)



		FY2018/3	FY2019/3		FY2020/3		FY2021/3 Forecast		
Billions of yen	_	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Imaging Products Business	Revenue	360.7	296.1	119.0	106.8	225.8	64.4	80.6	145.0
	Operating Profit	<b>30.2</b> (36.0)	<b>22.0</b> (22.6)	<b>2.0</b> (2.2)	-19.1 (-16.6)	-17.1 (-14.4)	<b>-27.4</b> (-26.1)	<b>-12.6</b> (-8.9)	<b>-40.0</b> (-35.0)
Precision	Revenue	226.3	274.5	117.6	127.4	245.0	63.8	126.2	190.0
Equipment	Operating	53.3	81.7	26.0	22.0	48.0	-6.0	10.0	4.0
Business	Profit	(53.3)	(81.7)	(26.0)	(22.0)	(48.0)	(-6.0)	(10.0)	(4.0)
Healthcare	Revenue	56.8	65.4	30.0	32.0	62.0	25.7	34.3	60.0
Business	Operating	-3.2	-1.9	-1.2	-1.2	-2.4	-2.3	-1.7	-4.0
	Profit	(-3.2)	(-1.9)	(-1.2)	(-1.2)	(-2.4)	(-2.3)	(-1.7)	(-4.0)
Industrial	Revenue	73.2	72.5	24.2	33.8	58.0	21.7	33.3	55.0
Metrology and Others	Operating	5.0	6.9	1.8	0	1.8	-2.9	0.9	-2.0
	Profit	(7.8)	(7.5)	(1.8)	(0)	(1.8)	(-2.9)	(0.9)	(-2.0)
Corporate P/L	Revenue	_	_	_	_	-	-	-	-
non-attributable to any reportable segments	operating	-29.1	-26.1	-11.1	-12.5	-23.6	-7.8	-15.2	-23.0
	Profit	(-29.1)	(-25.6)	(-9.4)	(-12.5)	(-21.9)	(-7.8)	(-15.2)	(-23.0)
Consolidated	Revenue	717.0	708.6	291.0	300.0	591.0	175.6	274.4	450.0
	Operating	56.2	82.6	17.5	-10.8	6.7	-46.6	-18.4	-65.0
	Profit	(64.9)	(84.4)	(19.4)	(-8.2)	(11.2)	(-45.3)	(-14.7)	(-60.0)

Note: Beginning in FY2019/3, some sales promotion costs will be deducted from revenue. Said costs had formally been posted in SG&A. Approximately ¥8.3B has been deducted from FY2019/3 revenue. Figures in parentheticals for operating profit exclude restructuring relevant expenses. The semiconductor related equipment business has been transferred to the Precision Equipment Business from Industrial Metrology and Others. Revenue of ¥5.3B and operating profit of ¥1.3B have been transferred to the Precision Equipment Business from Industrial Metrology and Others as a result of retroactive application to FY2020/3.


## 3rd quarter of the year ending March 31, 2021: Financial Highlights by Segment



		FY 2020/3			FY2021/3			
Billions of yen		Q1	Q2	Q3	Q4	Q1	Q2	Q3
	Revenue	67.3	51.7	70.0	36.8	25.1	39.3	52.3
Imaging Products Business	Operating	3.5	-1.5	-0.8	-18.3	-8.1	-19.3	-0.6
	Profit	(3.5)	(-1.3)	(-0.2)	(-16.4)	(-7.8)	(-18.3)	(0.0)
	Revenue	51.8	65.8	52.6	74.8	19.6	44.2	66.6
Precision Equipment Business	Operating	10.3	15.7	10.7	11.3	-5.1	-0.9	12.1
	Profit	(10.3)	(15.7)	(10.7)	(11.3)	(-5.1)	(-0.9)	(12.1)
Healthcare Business	Revenue	12.9	17.1	16.5	15.5	10.3	15.4	17.1
	Operating	-1.9	0.7	-0.4	-0.8	-2.4	0.1	0.7
	Profit	(-1.9)	(0.7)	(-0.4)	(-0.8)	(-2.4)	(0.1)	(0.7)
Industrial Metrology and Others	Revenue	10.8	13.4	14.3	19.5	9.5	12.2	14.5
	Operating	0.2	1.6	0.9	-0.9	-0.4	-2.5	1.4
	Profit	(0.2)	(1.6)	(0.9)	(-0.9)	(-0.4)	(-2.5)	(1.4)
Corporate P/L non- attributable to any reportable segments	Revenue	_	_	—	—	_	-	-
	Operating	-2.9	-8.2	-6.3	-6.2	-4.4	-3.4	-3.8
	Profit	(-2.9)	(-6.5)	(-6.3)	(-6.2)	(-4.4)	(-3.4)	(-3.8)
Consolidated	Revenue	142.9	148.1	153.4	146.6	64.7	110.9	150.6
	Operating	9.3	8.2	4.0	-14.8	-20.5	-26.1	9.9
	Profit	(9.3)	(10.1)	(4.7)	(-12.9)	(-20.2)	(-25.1)	(10.5)

Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.





Equity ratio 53.8% 53.7% 53.2%

Note: Equity ratio is ratio of equity attributable to owners of the parent to total assets. Cash and Cash Equivalents excludes time deposits with maturities of thee months or more.

### Forecast for the year ending March 31, 2021: Capital Expenditures, Depreciation and Inventory



#### CAPITAL EXPENDITURES, DEPRECIATION **INVENTORY BREAKDOWN** ¥50B ¥300B 266.5 253.3 250.0 246.5 245.1 Industrial 40 250 35.3 Metrology and 36.8 30.0 Others 30.9 34.1 35.8 33.9 17.3 33.4 31.7 Healthcare 15.0 32.2 15.7 17.8 30.0 200 16.0 27.8 28.7 30 26.0 24.9 150 160.5 136.6 146.8 20 160.0 Precision 157.8 100 Equipment 10 50 Imaging 64.2 53.4 51.0 45.0 35.5 Products C 0 19/319/12 21/320/320/1217/318/319/320/321/3Forecast Forecast Capital Expenditures Depreciation

Note: Capital expenditures in FY2020/3 includes the leased assets of approximately ¥4.0B upon the adoption of IFRS16.


Depreciation from FY2018/3 includes the amortization of capitalized R&D costs and in FY2020/3 depreciation of the leased asset includes approx. ¥7.0B, same as capital expenditures.

The semiconductor related equipment business has been transferred to the Precision Equipment Business from the Industrial Metrology and Others.

Inventory of ¥3.1B in the end of 2019/12 and ¥2.6B in the end of 2020/3 have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to FY2020/3 respectively.


### 1st to 3rd quarter of the year ending March 31, 2021: Revenue Breakdown





Note: The outside and inside circles show the breakdown of F2021/3 Q1-Q3 revenue of ¥326.2B and FY2020/3 Q1-Q3 revenue of ¥444.4B, respectively.






Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditure.


#### Cash Flow History





Note: FCF (free cash flows) = CF from operating activities + CF from investing activities; Japanese Standard is employed for FY2015/3 and prior, and IFRS is adopted for FY2016/3 and after. FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents






DCIL(Digtal Camera-Interchangeable Lens Type) Interchangeable Lens CDSC(Compact Digital Still Camera)


Forecast for the year ending March 31, 2021: Precision Equipment Business Sales Units






Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3, 34 units in FY2020/3 and 17 units (forecast) in FY2021/3.





G5/6 G7/8 G10.5





18/3-Q1 18/3-Q2 18/3-Q3 18/3-Q4 19/3-Q1 19/3-Q2 19/3-Q3 19/3-Q4 20/3-Q1 20/3-Q2 20/3-Q3 20/3-Q4 21/3-Q1 21/3-Q2 21/3-Q3

i-line KrF ArF ArF immersion



	Exchange Rate	Financial Impact from Fluctuation by 1 yen				
	FY2020/3 Forecast for Q4	Revenue Q4	Operating Profit Q4			
US \$	¥105	Approx. ¥0.6billion	Approx. ¥0.1billion			
EURO	¥115	Approx. ¥0.2billion	Approx. ¥0.1billion			

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and Euro.



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

